Generate a tailored SOP for Dr. Kristen Bubb. Improve your application with a focused, well-structured draft.
Kristen Bubb holds a PhD in Physiology and leads the Translational Vascular Therapeutics Group at Monash University's Department of Physiology within the Monash Biomedicine Discovery Institute and the Victorian Heart Institute research labs. She completed her training at Monash University and the William Harvey Research Institute in London, supported by a British Pharmacological Society International Fellowship in Clinical Pharmacology. Before returning to Monash in 2019, she co-led the Oxidative Signalling group at the Kolling Institute of Medical Research at the University of Sydney. Her research focuses on identifying novel therapeutic targets for cardiovascular diseases, particularly in the context of pulmonary hypertension (PH), which is characterized by progressive remodeling of the pulmonary vasculature leading to increased pulmonary vascular resistance and heart failure. Despite eight FDA-approved drugs for managing PH, treatment success remains suboptimal. Bubb aims to improve treatment efficacy and ultimately enhance patients' quality of life, investigating promising candidates through clinical samples and various models of targeted therapy. Her work is also related to the United Nations Sustainable Development Goals, emphasizing her commitment to impactful research in health science.
Monash University • Melbourne, Australia
Leading the Translational Vascular Therapeutics Group focusing on cardiovascular diseases.
University of Sydney • Sydney, Australia
Lectured on Vascular Biology and Molecular Physiology.
Requirements are standardized across the Faculty of Information Technology for most Master's programs including Computer Science and Data Science.